LBPH - Longboard Pharmaceuticals, Inc.
IEX Last Trade
35.99
0.450 1.250%
Share volume: 847,706
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
19.80%
PREVIOUS CLOSE
CHG
CHG%
$35.54
0.45
1.27%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
3.71%
1 Month
7.93%
3 Months
101.56%
6 Months
50.71%
1 Year
511.53%
2 Year
961.18%
Key data
Stock price
$35.99
DAY RANGE
N/A - N/A
52 WEEK RANGE
$3.60 - $40.48
52 WEEK CHANGE
$5.14
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Kevin R. Lind
Region: US
Website: longboardpharma.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: longboardpharma.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Longboard Pharmaceuticals, Inc. focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies.
Recent news